Article

Incidence, risk factors, and outcome of advanced NSCLC patients receiving antiangiogenic therapy with thromboembolic events: a retrospective cohort study

2022-10-19

Abstract excerpt

<h4>Background: </h4> Antiangiogenic therapy is widely used in advanced non-small cell lung cancer (NSCLC) patients. The purpose of this study was to investigate the incidence, risk factors, and outcome of advanced NSCLC patients receiving antiangiogenic therapy with thromboembolic events (TE). Methods This was a retrospective study, which included advanced NSCLC patients receiving antiangiogenic therapy from Mar...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3cda70b6-d91d-5072-9ab2-2c0411006944
DOI: 10.21203/rs.3.rs-2164834/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Incidence, risk factors, and outcome of advanced NSCLC patients receiving antiangiogenic therapy with thromboembolic events: a retrospective cohort studyDOI 10.21203/rs.3.rs-2164834/v1Read

Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer.Semantic proximity Read

Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: A cohort study.Semantic proximity Read

Thrombosis in Lung Cancer Research Trends: A Bibliometric AnalysisSemantic proximity Read

Concurrent chemotherapy and first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first-line treatment in advanced lung adenocarcinoma harboring an EGFR mutation.Semantic proximity Read

Identification of critical genes and pathways related to venous thromboembolism in non-small cell lung cancer patients using integrated bioinformatics analysisSemantic proximity Read

Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin: A real-world studySemantic proximity Read

[Research Progress of Angiogenesis Inhibitors Plus EGFR-TKI in EGFR-mutated Advanced Non-small Cell Lung Cancer].Semantic proximity Read

Clinical Phenotypes and Prognosis in Patients with Venous Thromboembolism and Cancer: A Cluster AnalysisSemantic proximity Read

The Efficacy And Safety of Anlotinib Combined With Platinum-Etoposide Chemotherapy As First-Line Treatment For Extensive-Stage Small Cell Lung Cancer: A Chinese Multicenter Real-World StudySemantic proximity Read

Application of Machine Learning to the Prediction of Cancer-Associated Venous ThromboembolismSemantic proximity Read

Common genetic driver mutation in NSCLC and their association with thromboembolic events: A retrospective study.Semantic proximity Read